Biopharma NewsBy
Trial Registered

Newsoara completes 515-patient Phase 3 of oral psoriasis drug HPP737 in China

The China-only trial tests PASI 75 response at 16 weeks against a crowded field of approved biologics and oral JAK/TYK2 rivals already sold for plaque psoriasis.

Newsoara HYK Biopharmaceutical completed a 515-patient Phase 3 trial of its oral small molecule HPP737 in adults with moderate-to-severe plaque psoriasis, run entirely in China.
By AppliedXLTrial NCT07712705

Executive Summary

  • Newsoara HYK Biopharmaceutical has completed a Phase 3 trial of its oral small molecule HPP737 in adults with moderate-to-severe plaque psoriasis, run entirely within China.
  • The primary endpoint asks how many patients clear at least three-quarters of their psoriasis skin involvement after four months of treatment, the standard bar regulators use to judge a psoriasis drug's efficacy.
  • Plaque psoriasis already has approved biologics and oral agents on the market, so HPP737 needs to show it can compete on response rate and tolerability rather than fill an open mechanism gap.
  • No efficacy or safety results have posted yet, and the trial's molecular target has not been disclosed, leaving its competitive position defined by trial design rather than by mechanism.

The trial

The trial, registered as NCT07712705, enrolled 515 adults with chronic plaque psoriasis across sites in China, randomizing them in a triple-masked, three-arm design. Enrollment reached its target of 515 patients, and the trial's primary completion date was set for September 29, 2023, with the study itself marked completed as of February 20, 2025. Patients had to show a Psoriasis Area and Severity Index score of at least 12, a static Physician's Global Assessment of at least 3, and body surface area involvement of at least 10% to qualify, criteria consistent with a moderate-to-severe population. NCT07712705HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.NCT07712705

The endpoint

The registered primary endpoint measures the proportion of patients who achieve PASI 75, a 75% or greater reduction from baseline in psoriasis severity, at week 16. Secondary measures track PASI 90 and PASI 100 response, static Physician's Global Assessment of clear or almost clear skin, body surface area change, and quality-of-life scores through week 52, along with a pharmacokinetic sub-study through week 12 and adverse event monitoring through week 54. That endpoint structure, PASI 75 at 16 weeks as primary with PASI 90/100 and long-term safety as secondary, mirrors the registrational design used across the psoriasis field. NCT07712705HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.NCT07712705

The competitive field

Plaque psoriasis has an established roster of approved treatments, including ustekinumab, adalimumab, and topical agents such as calcipotriene-betamethasone and tazarotene. HPP737 sits within a Phase 3 landscape of 255 small-molecule trials run in plaque psoriasis, alongside oral competitors including Takeda's zasocitinib and Bristol-Myers Squibb's deucravacitinib, both TYK2/JAK-pathway inhibitors advancing through Phase 3 psoriasis programs. HPP737's own molecular target has not been characterized in available data, so its competitive position rests on modality and indication rather than a mechanism comparison. Newsoara has run two other HPP737 trials in the same indication, a completed Phase 2 study and a second completed Phase 3 study comparing the drug against apremilast, giving the sponsor a three-trial program in plaque psoriasis alone.

What the readout would need to show

With multiple approved biologics and a growing bench of oral competitors already treating this population, a PASI 75 result at week 16 that clears placebo by a margin comparable to those already-approved options would be the threshold for HPP737 to matter competitively. The trial's operational profile is unremarkable: enrollment closed at its 515-patient target, the design held stable with no material protocol amendments recorded, and the study progressed to completion without registry-flagged distress. NCT07712705HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.NCT07712705

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.